JOHNSON & JOHNSON |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 147.5 USD | +1.23% |
|
-0.02% | -5.90% |
| 06:20pm | WHO Likely to Issue Wider Warning About J&J Cough Syrup Contamination, Reuters Reports | DJ |
| 01:47pm | WHO says wider alert on contaminated J&J cough syrup 'likely' | RE |
Presenter SpeechLaura Sutcliffe (Analysts)Good morning, everyone, and welcome back to day 2 of...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Sector
Pharmaceuticals
Calendar
2024-04-25
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
145.7
USD
Average target price
172.5
USD
Spread / Average Target
+18.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.90% | 351B | |
| +24.82% | 672B | |
| +24.08% | 550B | |
| +15.51% | 317B | |
| +7.19% | 292B | |
| +3.26% | 211B | |
| +0.78% | 203B | |
| -9.85% | 144B | |
| -6.65% | 141B | |
| -3.20% | 113B |
- Stock Market
- Equities
- JNJ Stock
- News Johnson & Johnson
- Transcript : Johnson & Johnson Presents at UBS Global Healthcare Conference, May-24-2022 10
